Clostridium difficile infection: Management strategies for a difficult disease

Therapeutic Advances in Gastroenterology

Volumn 7, Issue 2, 2014, Pages 72-86

  Khanna, Sahil ^a   Pardi, Darrell S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Clostridium difficile infection; management; recurrent infection; risk factors; severe infection

Indexed keywords

FIDAXOMICIN; IMMUNOGLOBULIN; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; PROBIOTIC AGENT; RIFAXIMIN; VANCOMYCIN;

ADVERSE OUTCOME; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; EPIDEMIC; FECES MICROFLORA; HUMAN; INCIDENCE; LONG TERM CARE; MEDICATION THERAPY MANAGEMENT; META ANALYSIS (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; RISK FACTOR; STOMACH ACID SECRETION; SYSTEMATIC REVIEW (TOPIC);

EID: 84893436171     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X13508519     Document Type: Review

References (111)

1. Abougergi M. Broor A. Cui W. Jaar B. (2010) Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med 5: E1–E9
2. Abougergi M. Kwon J. (2011) Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci 56: 19–26.
3. Ackermann G. Loffler B. Adler D. Rodloff A. (2004) In vitro activity of Opt-80 against Clostridium difficile. Antimicrob Agents Chemother 48: 2280–2282.
4. Allard R. Dascal A. Camara B. Letourneau J. Valiquette L. (2011) Community-acquired Clostridium difficile-associated diarrhea, Montreal, 2005-2006: frequency estimates and their validity. Infect Control Hosp Epidemiol 32: 1032–1034.
5. Allen S. Wareham K. Wang D. Bradley C. Hutchings H. Harris W. et al. (2013) Lactobacilli and Bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (placide): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet S0140-6736 (13): 61218–61220.
6. Bakken J. Borody T. Brandt L. Brill J. Demarco D. Franzos M. et al. (2011) Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 9: 1044–1049.
7. Bartlett J. Chang T. Gurwith M. Gorbach S. Onderdonk A. (1978) Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 298: 531–534.
8. Bartsch S. Umscheid C. Fishman N. Lee B. (2013) Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis 57: 555–561.
9. Belmares J. Gerding D. Parada J. Miskevics S. Weaver F. Johnson S. (2007) Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect 55: 495–501.
10. Berman A. (2007) Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea. J Clin Gastroenterol 41: 932–933.
11. Brandt L. (2013) Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol 108 (2): 177–185.
12. Brandt L. Aroniadis O. (2013) An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc 78: 240–249.
13. Brandt L. Aroniadis O. Mellow M. Kanatzar A. Kelly C. Park T. et al. (2012) Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 107 (7): 1079–1087.
14. Cadle R. Mansouri M. Logan N. Kudva D. Musher D. (2007) Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm 64: 2359–2363.
15. Carroll K. (2011) Tests for thediagnosis of Clostridium difficile infection: the next generation. Anaerobe 17: 170–174.
16. Centers for Disease Control and Prevention (2012) Vital signs: preventing Clostridium difficile infections. MMWR Surveill Summ 61: 157–162.
17. Chitnis A. Holzbauer S. Belflower R. Winston L. Bamberg W. Lyons C. et al. (2013) Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med 173: 1359–1367.
18. Cohen S. Gerding D. Johnson S. Kelly C. Loo V. McDonald L. et al. (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31: 431–455.
19. Cornely O. Crook D. Esposito R. Poirier A. Somero M. Weiss K. et al. (2012) Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12: 281–289.
20. Dial S. Delaney J. Barkun A. Suissa S. (2005) Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294: 2989–2995.
21. Dial S. Delaney J. Schneider V. Suissa S. (2006) Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 175: 745–748.
22. Dubberke E. Gerding D. Classen D. Arias K. Podgorny K. Anderson D. et al. (2008) Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol 29(Suppl. 1): S81–S92
23. Dupont H. Jiang Z. Okhuysen P. Ericsson C. de La Cabada F. Ke S. et al. (2005) A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea. Ann Intern Med 142: 805–812.
24. El Feghaly R. Stauber J. Deych E. Gonzalez C. Tarr P. Haslam D. (2013) Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis 56: 1713–1721.
25. Finegold S. Molitoris D. Vaisanen M. Song Y. Liu C. Bolanos M. (2004) In vitro activities of Opt-80 and Comparator drugs against intestinal Bacteria. Antimicrob Agents Chemother 48: 4898–4902.
26. Fujii L. Fasolino J. Crowell M. Di Baise J. (2010) Prior appendectomy is not associated with an increased risk of Clostridium difficile relapse. Am J Gastroenterol 105: 393.
27. Fujitani S. George W. Murthy A. (2011) Comparison of clinical severity score indices for Clostridium difficile infection. Infect Control Hosp Epidemiol 32: 220–228.
28. Garey K. Ghantoji S. Shah D. Habib M. Arora V. Jiang Z. et al. (2011) A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 66 (12): 2850–2855.
29. Garey K. Sethi S. Yadav Y. Dupont H. (2008) Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 70: 298–304.
30. Gerber M. Ackermann G. (2008) Opt-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review. Expert Opin Invest Drugs 17: 547–553.
31. Gough E. Shaikh H. Manges A. (2011) Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 53: 994–1002.
32. Hamilton M. Weingarden A. Sadowsky M. Khoruts A. (2012) Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 107 (5): 761–767.
33. Hu M. Katchar K. Kyne L. Maroo S. Tummala S. Dreisbach V. et al. (2009) Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 136: 1206–1214.
34. Im G. Modayil R. Lin C. Geier S. Katz D. Feuerman M. et al. (2011) The appendix may protect against Clostridium difficile recurrence. Clin Gastroenterol Hepatol 9: 1072–1077.
35. Jhung M. Thompson A. Killgore G. Zukowski W. Songer G. Warny M. et al. (2008) Toxinotype V Clostridium difficile in humans and food animals. Emerg Infect Dis 14: 1039–1045.
36. Johnson S. (2009) Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 58: 403–410.
37. Johnson S. Gerding D. (2013) Fidaxomicin ‘chaser’ regimen following vancomycin for patients with multiple Clostridium difficile recurrences. Clin Infect Dis 56: 309–310.
38. Johnston B. Ma S. Goldenberg J. Thorlund K. Vandvik P. Loeb M. et al. (2012) Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 157: 878–888.
39. Johnson S. Schriever C. Galang M. Kelly C. Gerding D. (2007) Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 44: 846–848.
40. Karlowsky J. Laing N. Zhanel G. (2008) In vitro activity of Opt-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 52: 4163–4165.
41. Keddis M. Khanna S. Noheria A. Baddour L. Pardi D. Qian Q. (2012) Clostridium difficile infection in patients with chronic kidney disease. Mayo Clinic Proc 87: 1046–1053.
42. Kelly C. (2013) Fecal microbiota transplantation–an old therapy comes of age. N Engl J Med 368: 474–475.
43. Kelly C. Lamont J. (2008) Clostridium difficile–more difficult than ever. N Engl J Med 359: 1932–1940.
44. Khanna S. Aronson S. Kammer P. Baddour L. Pardi D. (2012 a) Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study. Mayo Clin Proc 87: 636–642.
45. Khanna S. Baddour L. Di Baise J. Pardi D. (2013 a) Appendectomy is not associated with adverse outcomes in Clostridium difficile infection: a population-based study. Am J Gastroenterol 108: 626–627.
46. Khanna S. Baddour L. Huskins W. Kammer P. Faubion W. Zinsmeister A. et al. (2013 b) The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis 56: 1401–1406.
47. Khanna S. Keddis M. Noheria A. Baddour L. Pardi D. (2013 c) Acute kidney injury is an independent marker of severity in Clostridium difficile infection: a nationwide survey. J Clin Gastroenterol 47: 481–484.
48. Khanna S. Pardi D. (2010) The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol 4: 409–416.
49. Khanna S. Pardi D. (2012 b) Clostridium difficile infection: new insights into management. Mayo Clin Proc 87: 1106–1117.
50. Khanna S. Pardi D. (2012 c) Community acquired Clostridium difficile infection: an emerging entity, Clin Infect Dis 55: 1741–1742.
51. Khanna S. Pardi D. (2012 d) Gastric acid suppression and Clostridium difficile infection: is there a causal connection? Clin Gastroenterol Hepatol 10: 564.
52. Khanna S. Pardi D. (2012 e) IBD: poor outcomes after Clostridium difficile infection in IBD. Nat Rev Gastroenterol Hepatol 9: 307–308.
53. Khanna S. Pardi D. Aronson S. Kammer P. Baddour L. (2012 f) Outcomes in community-acquired Clostridium difficile infection. Aliment Pharmacol Therapeut 35: 613–618.
54. Khanna S. Pardi D. Aronson S. Kammer P. Orenstein R. St Sauver J. et al. (2012 g) The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 107: 89–95.
55. Khanna S. Pardi D. Rosenblatt J. Patel R. Kammer P. Baddour L. (2012 h) An evaluation of repeat stool testing for Clostridium difficile infection by polymerase chain reaction. J Clin Gastroenterol 46: 846–849.
56. Kim J. Lee K. Jeong J. Kim B. Shin S. Kim J. et al. (2010) Proton pump inhibitors as a risk factor for recurrence of Clostridium difficile-associated diarrhea. World J Gastroenterol 16: 3573–3577.
57. Kim J. Smathers S. Prasad P. Leckerman K. Coffin S. Zaoutis T. (2008) Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 122: 1266–1270.
58. Koo H. Dupont H. (2010) Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 26: 17–25.
59. Kuntz J. Chrischilles E. Pendergast J. Herwaldt L. Polgreen P. (2011) Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study. BMC Infect Dis 11: 194.
60. Lancaster J. Matthews S. (2012) Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections. Clin Ther 34: 1–13.
61. Leav B. Blair B. Leney M. Knauber M. Reilly C. Lowy I. et al. (2010) Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28: 965–969.
62. Lessa F. (2013) Community-associated Clostridium difficile infection: how real is it? Anaerobe S1075-9964 (13): 00019-X.
63. Linsky A. Gupta K. Hermos J. (2011) Fidaxomicin for Clostridium difficile infection. N Engl J Med 364: 1875; author reply 1875–1876.
64. Linsky A. Gupta K. Lawler E. Fonda J. Hermos J. (2010) Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Int Med 170: 772–778.
65. Louie T. Miller M. Mullane K. Weiss K. Lentnek A. Golan Y. et al. (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364: 422–431.
66. Lowy I. Molrine D. Leav B. Blair B. Baxter R. Gerding D. et al. (2010) Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362: 197–205.
67. Lungulescu O. Cao W. Gatskevich E. Tlhabano L. Stratidis J. (2011) CSI: a severity index for Clostridium difficile infection at the time of admission. J Hosp Infect 79: 151–154.
68. Marx C. Morris A. Wilson M. Reller L. (1993) Fecal leukocytes in stool specimens submitted for Clostridium difficile toxin assay. Diagn Microbiol Infect Dis 16: 313–315.
69. Mattila E. Uusitalo-Seppala R. Wuorela M. Lehtola L. Nurmi H. Ristikankare M. et al. (2012) Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 142: 490–496.
70. McDonald L. Owings M. Jernigan D. (2006) Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 12: 409–415.
71. McFarland L. (2010) Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 16: 2202–2222.
72. McFarland L. Elmer G. Surawicz C. (2002) Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97: 1769–1775.
73. McFarland L. Surawicz C. Greenberg R. Fekety R. Elmer G. Moyer K. et al. (1994) A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271: 1913–1918.
74. Merchant R. Mower W. Ourian A. Abrahamian F. Moran G. Krishnadasan A. et al. (2012) Association between appendectomy and Clostridium difficile infection. J Clin Med Res 4: 17–19.
75. Miller B. Chen L. Sexton D. Anderson D. (2011) Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus Aureus in community hospitals. Infect Control Hosp Epidemiol 32: 387–390.
76. Mullane K. Miller M. Weiss K. Lentnek A. Golan Y. Sears P. et al. (2011) Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 53: 440–447.
77. Musher D. Aslam S. Logan N. Nallacheru S. Bhaila I. Borchert F. et al. (2005) Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40: 1586–1590.
78. Musher D. Logan N. Bressler A. Johnson D. Rossignol J. (2009) Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 48: e41–e46
79. Musher D. Logan N. Hamill R. Dupont H. Lentnek A. Gupta A. et al. (2007) Nitazoxanide versus metronidazole for Clostridium difficile-associated colitis – reply to Young et al. Clin Infect Dis 44: 152–154.
80. Muto C. Pokrywka M. Shutt K. Mendelsohn A. Nouri K. Posey K. et al. (2005) A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 26: 273–280.
81. Neal M. Alverdy J. Hall D. Simmons R. Zuckerbraun B. (2011) Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 254: 423–427.
82. Orenstein R. (2012) Fidaxomicin failures in recurrent Clostridium difficile infection a problem of timing. Clin Infect Dis 55 (4): 613–614.
83. Orenstein R. Aronhalt K. Mcmanus J. Fedraw L. (2011) A targeted strategy to wipe out Clostridium difficile. Infect Control Hosp Epidemiol 32: 1137–1139.
84. Otten A. Reid-Smith R. Fazil A. Weese J. (2010) Disease transmission model for community-associated Clostridium difficile infection. Epidemiol Infect 138: 907–914.
85. Pardi D. Brennan R. Spinnell M. Gareca M. Greenberg E. Tian W. et al. (2012) The efficacy and safety of rifaximin vs. vancomycin in the treatment of mild to moderate C. difficile infection: a randomized double-blind active comparator trial. Gastroenterology 142: S-599.
86. Pepin J. Alary M. Valiquette L. Raiche E. Ruel J. Fulop K. et al. (2005 a) Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40: 1591–1597.
87. Pepin J. Saheb N. Coulombe M. Alary M. Corriveau M. Authier S. et al. (2005 b) Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41: 1254–1260.
88. Pepin J. Valiquette L. Alary M. Villemure P. Pelletier A. Forget K. et al. (2004) Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171: 466–472.
89. Pillai A. Nelson R. (2008) Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev: CD004611.
90. Rao A. Jump R. Pultz N. Pultz M. Donskey C. (2006) In vitro killing of nosocomial pathogens by acid and acidified nitrite. Antimicrob Agents Chemother 50: 3901–3904.
91. Reddymasu S. Sheth A. Banks D.E. (2006) Is fecal leukocyte test a good predictor of Clostridium difficile associated diarrhea? Ann Clin Microbiol Antimicrob 5: 9.
92. Ricciardi R. Rothenberger D. Madoff R. Baxter N. (2007) Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 142: 624–631; discussion 631.
93. Rubin D. Sohi S. Glathar M. Thomas T. Yadron N. Surma B. (2011) Rifaximin is effective for the treatment of Clostridium difficile-associated diarrhea: results of an open-label pilot study. Gastroenterol Res Pract 2011: 106978.
94. Shivashankar R. Khanna S. Kammer P. Harmsen W. Zinsmeister A. Baddour L. et al. (2013) Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol S1542-3565 (13): 00685-X.
95. Sloan L. Duresko B. Gustafson D. Rosenblatt J. (2008) Comparison of real-time PCR for detection of the TCDC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J Clin Microbiol 46: 1996–2001.
96. Stranges P. Hutton D. Collins C. (2013) Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 16: 297–304.
97. Surawicz C. Brandt L. Binion D. Ananthakrishnan A. Curry S. Gilligan P. et al. (2013) Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108: 478–498.
98. Surawicz C. McFarland L. Elmer G. Chinn J. (1989) Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol 84: 1285–1287.
99. Surawicz C. McFarland L. Greenberg R. Rubin M. Fekety R. Mulligan M. et al. (2000) The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31: 1012–1017.
100. Teasley D. Gerding D. Olson M. Peterson L. Gebhard R. Schwartz M. et al. (1983) Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 2: 1043–1046.
101. Tedesco F. Gordon D. Fortson W. (1985) Approach to patients with multiple relapses of antibiotic-associated Pseudomembranous colitis. Am J Gastroenterol 80: 867–868.
102. Tsiouris A. Neale J. Reickert C. Times M. (2012) Clostridium difficile of the ileum following total abdominal colectomy, with or without proctectomy: who is at risk? Dis Colon Rectum 55: 424–428.
103. van Nood E. Vrieze A. Nieuwdorp M. Fuentes S. Zoetendal E. de Vos W. et al. (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368 (5): 407–415.
104. Villano S. Seiberling M. Tatarowicz W. Monnot-Chase E. Gerding D. (2012) Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother 56: 5224–5229.
105. Weese J. Reid-Smith R. Avery B. Rousseau J. (2010) Detection and characterization of Clostridium difficile in retail chicken. Lett Appl Microbiol 50: 362–365.
106. Wenisch C. Parschalk B. Hasenhundl M. Hirschl A. Graninger W. (1996) Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 22: 813–818.
107. Wilson K. Sheagren J. Freter R. (1985) Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster. J Infect Dis 151: 355–361.
108. Wullt M. Hagslatt M. Odenholt I. (2003) Lactobacillus plantarum 299V for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 35: 365–367.
109. Zar F. Bakkanagari S. Moorthi K. Davis M. (2007) A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45: 302–307.
110. Zilberberg M. Shorr A. Kollef M. (2008 a) Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 14: 929–931.
111. Zilberberg M. Shorr A. Kollef M. (2008 b) Increase in Clostridium difficile-related hospitalizations among infants in the United States, 2000-2005. Pediatr Infect Dis J 27: 1111–1113.